MYR Pharma's Bulevirtide has been awarded a Promising Innovative Medicine as a treatment for hepatitis D infections, indicating that the drug is a strong contender for the UK's Early Access to Medicinces Scheme (EAMS).Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.